A recent study has found that cell gas pretreatment for viral infections can be predicted through real-time observation.
In the study published in the journal Biomaterials, therapeutic efficacy was predicted using initial circulation images of gas cells that are different from endothelial cells. It can be applied in research in the field of gas cell therapies for blood vessel regeneration.
In recent years, the number of high-risk groups for ischemic diseases such as critical ischemia where toe bones may decay is on the rise due to an increase in the number of people with obesity, diabetes and hip intolerance caused by changes in diet habits, smoking and alcohol consumption. Several studies have been performed on endothelial progenitor cells (hEPCs), which are gas cells that contribute to blood vessel regeneration in the ischemic glands, to treat such ischemia diseases.
Vascular hEPCs migrate to areas requiring angiogenesis, such as ischemic regions, and then differentiate into endothelial cells of blood vessels or release growth factors that help blood vessel formation to regenerate. -to stimulate the renewal of damaged blood vessels. Thus, these cells can be developed into cell gas for diseases involving blood vessels including ischemic diseases.
However, when the hEPCs with blood vessel regeneration ability are used as gas cell treatment in ischemic diseases, the effectiveness of therapeutic treatment can vary according to various variables such as survival of transplanted cells and migration to the region. treatment. Accordingly, treatments for ischemic diseases remain in the clinical stage without being trafficked due to so few limitations in properly observing and predicting therapeutic efficacy.
The Korea Institute of Science and Technology (KIST) recently announced that the collaborative research team led by Dr. Kwangmeyung Kim from the Center for Theragnosis and Sung-Hwan Moon from the Stem Cell Research Institute, T&R Biofab Co. Ltd. a therapeutic efficacy method based on the transmission of the first transmission of hEPCs by monitoring the initial dispersion and migration of transplanted cells using romantic fluorescence imaging.
The KIST research team first allowed observation of fluorescence signals through fluorescence molecular tomography by attaching fluorescent dyes to the surface of hEPCs. The team then inserted the cells into the end limb of the mouse with severe ischemia of the arms and detected them through images for 28 days to assess cell movement in the body; then, monitoring and monitoring the blood flow regeneration process through a laser scanning microscope (Laser Doppler images). As a result, it has been revealed that the hEPCs migrate to the damaged tissues where the ischemic disease is found.
In addition, the shapes of cell plates were introduced into two different shapes as a result of image analysis of hEPCs during the first reprogramming of cell therapy treatment. Both shapes were circular and diffuse-shaped. When therapeutic efficacy was observed by classifying the experimental groups into these two shapes, it was found that the original ‘round-shaped’ cells produced better migration and showed better therapeutic efficacy in the experimental groups. Based on these findings, the research team predicted that the treatment efficiency will be better when the treated cells are formed in a thick ‘round shape’ during the initial treatment.
“Our advanced technology, which will be able to quickly and accurately monitor the initial regression forms and changes in cell gas treatment, will allow to predict the effectiveness of transmitted hEPCs in the early stages. of ischemic disease treatment, and we expect it to be used in the development of stem gas treatments for ischemic diseases in the future, ”said Dr. Kwangmeyung Kim at KIST, who led the research.
(This story was published from a wire group group with no text changes. Only the headline was changed.)
Follow more stories on Facebook and Twitter